Clinical Trials Logo

Breast Neoplasm Female clinical trials

View clinical trials related to Breast Neoplasm Female.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04778670 Active, not recruiting - Clinical trials for Breast Neoplasm Female

Artificial Intelligence in Large-scale Breast Cancer Screening

ScreenTrustCAD
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This is a prospective clinical trial following a paired screen-positive design, with the aims to assess the performance of an artificial intelligence (AI) computer-aided detection (CAD) algorithm as an independent reader, in addition to two radiologists, of screening mammograms in a true screening population. Since all decisions by individual readers will be recorded, it is possible to determine what the outcome would have been had one or two of the readers not been allowed to assess images, and to determine what the outcome would have been had the recall decision been performed by consensus decision (actual) compared to single reader arbitration of discordant cases.

NCT ID: NCT03691311 Active, not recruiting - Clinical trials for Stage II Breast Cancer

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

D-BIOMARK
Start date: July 5, 2018
Phase: Early Phase 1
Study type: Interventional

This is a biomarker study designed to test the preclinically generated hypothesis of anti-tumoral activity of denosumab in patients with early breast cancer candidates a tumour excision

NCT ID: NCT03650894 Active, not recruiting - Breast Cancer Clinical Trials

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Start date: April 3, 2019
Phase: Phase 2
Study type: Interventional

The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and immune checkpoint therapy.

NCT ID: NCT03425838 Active, not recruiting - Clinical trials for Breast Neoplasm Female

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Start date: November 9, 2017
Phase: Phase 3
Study type: Interventional

Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence of an aromatase inhibitor in first line followed by fulvestrant plus CDK4/6 in second line.